Effect of Continuous Glucose Monitoring on Glycemic Control, Acute Admissions, and Quality of Life: A Real-World Study
Open accessThe DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
Context: Randomized controlled trials evaluating real-time continuous glucose monitoring (RT-CGM) patients with type 1 diabetes (T1D) show improved glycemic control, but limited data are available on real-world use. Objective: To assess impact of RT-CGM in real-world settings on glycemic control, hospital admissions, work absenteeism, and quality of life (QOL). Design: Prospective, observational, multicenter, cohort study. Participants: A total of 515 adults with T1D on continuous subcutaneous insulin infusion (CSII) therapy starting in the Belgian RT-CGM reimbursement program. Intervention: Initiation of RT-CGM reimbursement. Main Outcome Measure: Hemoglobin A1c (HbA1c) evolution from baseline to 12 months. Results: Between September 1, 2014, and December 31, 2016, 515 adults entered the reimbursement system. Over this period, 417 (81%) patients used RT-CGM for at least 12 months. Baseline HbA1c was 7.7 ± 0.9% (61 ± 9.8 mmol/mol) and decreased to 7.4 ± 0.8% (57 ± 8.7 mmol/mol) at 12 months (P < 0.0001). Subjects who started RT-CGM because of insufficient glycemic control showed stronger decrease in HbA1c at 4, 8, and 12 months compared with patients who started because of hypoglycemia or pregnancy. In the year preceding reimbursement, 16% of patients were hospitalized for severe hypoglycemia or ketoacidosis in contrast to 4% (P < 0.0005) the following year, with decrease in admission days from 54 to 18 per 100 patient years (P < 0.0005). In the same period, work absenteeism decreased and QOL improved significantly, with strong decline in fear of hypoglycemia. Conclusion: Sensor-augmented pump therapy in patients with T1D followed in specialized centers improves HbA1c, fear of hypoglycemia, and QOL, whereas work absenteeism and admissions for acute diabetes complications decreased.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Benefits of CGM in this population include reductions in A1C, fewer severe hypoglycemia events in children and adults, increased TIR, as well as significant reductions in hospitalizations for severe hypoglycemia and DKA.156,162–168”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [165]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SPSS survival manual : a step by step guide to data analysis using SPSS
Pallant, J. (2010) · Cited by 6,888
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069 · cited 1×
“statement (11), our trial reports on time in hypoglycemia, time in range, and glucose variability.”
BackgroundContinuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Assessment of Diabetes-Related Distress
Polonsky, W. H., Anderson, B. J., Lohrer, P. A., Welch, G., Jacobson, A. M., Aponte, J. E., & Schwartz, C. E. (1995) · Diabetes Care · doi:10.2337/diacare.18.6.754 · Cited by 1,497
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002853 · Cited by 894
Hex, N., Bartlett, C., Wright, D., Taylor, M., & Varley, D. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03698.x · Cited by 819 · cited 1×
“Of interest, we also observed a decline in work absenteeism, which is a less visible (but substantial) financial burden to society (22).”
BackgroundFear of hypoglycemia: quantification, validation, and utilization
Cox, D. J., Irvine, A., Gonder-Frederick, L., Nowacek, G., & Butterfield, J. (1987) · Diabetes Care · doi:10.2337/diacare.10.5.617 · Cited by 579 · cited 1×
“All questionnaires [SF-36 (12), Problem Areas in Diabetes-short form (13–15), andHypoglycemia Fear Survey (HFS)-Worry (16, 17)] were validated in both Belgian languages (Dutch and French) and presented to patients in their mother tongue (Supplemental Table 2).”
Backgroundthe SWITCH Study Group, Battelino, T., Conget, I., Olsen, B., Schütz-Fuhrmann, I., Hommel, E., Hoogma, R., Schierloh, U., Sulli, N., & Bolinder, J. (2012) · Diabetologia · doi:10.1007/s00125-012-2708-9 · Cited by 494
McGuire, B. E., Morrison, T. G., Hermanns, N., Skovlund, S., Eldrup, E., Gagliardino, J., Kokoszka, A., Matthews, D., Pibernik-Okanović, M., Rodríguez-Saldaña, J., et al. (2010) · Diabetologia · doi:10.1007/s00125-009-1559-5 · Cited by 424 · cited 1×
“Additionally, almost half of the patients in the RESCUE trial reported problematic emotional distress (15).”
BackgroundPsychometric properties of the hypoglycemia fear survey-ii for adults with type 1 diabetes
Gonder-Frederick, L. A., Schmidt, K. M., Vajda, K. A., Greear, M. L., Singh, H., Shepard, J. A., & Cox, D. J. (2011) · Diabetes Care · doi:10.2337/dc10-1343 · Cited by 337
Real-time continuous glucose monitoring among participants in the T1D Exchange clinic registry
Wong, J. C., Foster, N. C., Maahs, D. M., Raghinaru, D., Bergenstal, R. M., Ahmann, A. J., Peters, A. L., Bode, B. W., Aleppo, G., Hirsch, I. B., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0303 · Cited by 318
O’Connell, M. A., Donath, S., O’Neal, D. N., Colman, P. G., Ambler, G. R., Jones, T. W., Davis, E. A., & Cameron, F. J. (2009) · Diabetologia · doi:10.1007/s00125-009-1365-0 · Cited by 211
El Achhab, Y., Nejjari, C., Chikri, M., & Lyoussi, B. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.12.020 · Cited by 172
Hermanides, J., Nørgaard, K., Bruttomesso, D., Mathieu, C., Frid, A., Dayan, C. M., Diem, P., Fermon, C., Wentholt, I. M. E., Hoekstra, J. B. L., et al. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03256.x · Cited by 169 · cited 4×
“1228 Charleer et al Real-World Impact of RT-CGM Reimbursement J Clin Endocrinol Metab, March 2018, 103(3):1224–1232”
BackgroundInfluentialSelf-citationBattelino, T., Nimri, R., Dovč, K., Phillip, M., & Bratina, N. (2017) · Diabetes Care · doi:10.2337/dc16-2584 · Cited by 157 · cited 1×
“New generations of so-called sensor-augmented pump (SAP) systems are able to reduce time spent in hypoglycemia by suspending insulin infusion when glucose is (predicted to be) low (4, 5).”
BackgroundNicolucci, A., Maione, A., Franciosi, M., Amoretti, R., Busetto, E., Capani, F., Bruttomesso, D., Bartolo, P. D., Girelli, A., Leonetti, F., et al. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02346.x · Cited by 117
Routine Sensor-Augmented Pump Therapy in Type 1 Diabetes: The INTERPRET Study
Nørgaard, K., Scaramuzza, A. E., Bratina, N., Lalic, N. M., Jarosz-Chobot, P. A., Kocsis, G., Jašinskienė, E., Block, C. E. M. D., Carrette, O., Castañeda, J., et al. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0288 · Cited by 112
Riveline, J., Schaepelynck, P., Chaillous, L., Renard, É., Sola‐Gazagnes, A., Penfornis, A., Tubiana‐Rufi, N., Sulmont, V., Catargi, B., Lukas, C., et al. (2012) · Diabetes Care · doi:10.2337/dc11-2021 · Cited by 99
Self-citationBlevins, T. C., Bode, B. W., Garg, S. K., Grunberger, G., Hirsch, I. B., Jovanovič, L., Nardacci, E., Orzeck, E. A., Roberts, V. L., & Tamborlane, W. V. (2010) · Endocrine Practice · doi:10.4158/ep.16.5.730 · Cited by 98
Continuous Glucose Monitoring and Global Reimbursement: An Update
Graham, C. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0096 · Cited by 66 · cited 1×
“criteria that vary per health insurance system (6, 7, 26, 29, 30).”
BackgroundRoutine use of continuous glucose monitoring in 10 501 people with diabetes mellitus
Battelino, T., Liabat, S., Veeze, H. J., Castañeda, J., Arrieta, A., & Cohen, O. (2015) · Diabetic Medicine · doi:10.1111/dme.12825 · Cited by 63
Hypoglycemia Reduction and Changes in Hemoglobin A1c in the ASPIRE In-Home Study
Weiss, R., Garg, S. K., Bode, B. W., Bailey, T. S., Ahmann, A. J., Schultz, K. A., Welsh, J. B., Shin, J. J., & for the ASPIRE In-Home Study Group (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0306 · Cited by 56 · cited 1×
“New generations of so-called sensor-augmented pump (SAP) systems are able to reduce time spent in hypoglycemia by suspending insulin infusion when glucose is (predicted to be) low (4, 5).”
BackgroundReimbursement for Continuous Glucose Monitoring: A European View
Heinemann, L., Franc, S., Phillip, M., Battelino, T., Ampudia-Blasco, F. J., Bolinder, J., Diem, P., Pickup, J., & DeVries, J. H. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600631 · Cited by 49 · cited 1×
“criteria that vary per health insurance system (6, 7, 26, 29, 30).”
BackgroundContinuous Home Monitoring of Glucose
Garg, S. K., Kelly, W. C., Voelmle, M. K., Ritchie, P. J., Gottlieb, P. A., McFann, K., & Ellis, S. L. (2007) · Diabetes Care · doi:10.2337/dc07-1436 · Cited by 48
Tu, Y., Bælum, V., & Gilthorpe, M. S. (2005) · European Journal Of Oral Sciences · doi:10.1111/j.1600-0722.2005.00229.x · Cited by 40
Reimbursement for Continuous Glucose Monitoring
Heinemann, L., & DeVries, J. H. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0296 · Cited by 40
Gómez, A. M., Carrillo, L. F. M., Múñoz, Ó., Rondón, M., Correa, C. M. A., Garzón, E. M., Diaz, M. C. C., & Henao, D. C. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0332 · Cited by 32 · cited 1×
“Hospital admissions for acute diabetes complications decreased significantly, in particular for severe hypoglycemia, to a similar extent as described with SAP with low glucose-suspend function (21).”
Background&NA; (1996) · AJN American Journal of Nursing · doi:10.1097/00000446-199601001-00015 · Cited by 10
Research works printed but not linked: 1
- Ware, 1993, SF-36 Health Survey: Manual and Interpretation Guide
Cited by
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement
Battelino, T., Alexander, C. M., Amiel, S. A., Arreaza-Rubin, G., Beck, R. W., Bergenstal, R. M., Buckingham, B. A., Carroll, J., Ceriello, A., Chow, E., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00319-9 · Cited by 831
Self-citationBlonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Dhatariya, K. K., Glaser, N. S., Codner, E., & Umpierrez, G. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0165-1 · Cited by 461
Grunberger, G., Sherr, J., Allende, M., Blevins, T., Bode, B., Handelsman, Y., Hellman, R., Lajara, R., Roberts, V. L., Rodbard, D., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.04.008 · Cited by 288
Charleer, S., De Block, C., Van Huffel, L., Broos, B., Fieuws, S., Nobels, F., Mathieu, C., & Gillard, P. (2020) · Diabetes Care · doi:10.2337/dc19-1610 · Cited by 261
Self-citation
Metadata
- Authors
- Charleer, S., Mathieu, C., Nobels, F., De Block, C., Radermecker, R. P., Hermans, M. P., Taes, Y., Vercammen, C., T'Sjoen, G., Crenier, L., Fieuws, S., Keymeulen, B., Gillard, P., & RESCUE Trial Investigators
- Affiliations
- Research Foundation - Flanders (BE)
- KU Leuven (BE)
- Onze Lieve Vrouwziekenhuis Hospital (BE)
- Department of Endocrinology, Diabetology and Metabolism, University of Antwerp–Antwerp University Hospital, Antwerp, Belgium
- Department of Diabetes, Nutrition and Metabolic Disorders, Centre Hospitalier Universitaire Liege–Liege University, Liege, Belgium
- Cliniques Universitaires Saint-Luc (BE)
- AZ Sint-Jan (BE)
- Imelda Hospital (BE)
- Ghent University Hospital (BE)
- Université Libre de Bruxelles (BE)
- Hasselt University (BE)
- Vrije Universiteit Brussel (BE)
- Corresponding author
- Gillard, Pieter
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2018-01-12
- Volume
- 103
- Issue
- 3
- Pages
- 1224-1232
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2791573153
- Cited by
- 196
- References
- 29
- Citations by year
- 2026: 14 · 2025: 23 · 2024: 23 · 2023: 22 · 2022: 27 · 2021: 39 · 2020: 15 · 2019: 22 · 2018: 11
- FWCI
- 17.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Lirias (submittedVersion, other-oa)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- Document Server@UHasselt (UHasselt) (submittedVersion)
- ORBi (University of Liège) (submittedVersion, other-oa)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Fonds Wetenschappelijk Onderzoek (10.13039/501100003130, http://dx.doi.org/10.13039/501100003130, 1S13517N, 501100003130)
- Vlaamse regering
- Horizon 2020 Framework Programme
- Universitaire Ziekenhuizen Leuven, KU Leuven
- H2020 European Institute of Innovation and Technology (http://dx.doi.org/10.13039/100010686)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- continuous glucose monitoring, type 1 diabetes, glycemic control, HbA1c, hospitalization, absenteeism, quality of life, fear of hypoglycemia, insulin pump therapy, sensor-augmented pump therapy, hypoglycemia, diabetic ketoacidosis
- MeSH terms
- Adult, Blood Glucose, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Hospitalization, Humans, Hypoglycemia, Male, Middle Aged, Prospective Studies, Quality of Life, Blood Glucose Self-Monitoring
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.